13 results on '"Sriuranpong, V."'
Search Results
2. EP08.04-003 A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
3. FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
4. P42.02 Prognostic Indicators for Conventional Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients in Resource-Limited Country
5. OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
6. P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
7. P018 Afatinib Named Patient Use Program in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers
8. P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers
9. OA02.05 CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial
10. P2.01-104 Plasma T-Cell-Derived Circulating DNA in Advanced NSCLC is Not Correlated with TIL but has a Potential of Prognostic Value
11. OA 05.02 Osimertinib vs SoC EGFR-TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA): Plasma ctDNA Analysis
12. P3.01-042 Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study
13. Epithelial-Specific Methylation Marker: A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.